Advertisement
Advertisement
U.S. markets open in 7 hours 11 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Jiayin Group Inc. (JFIN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.6800-0.3100 (-10.37%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Bollinger Bands

Bollinger Bands

Previous Close2.9900
Open3.0300
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range2.6100 - 2.9785
52 Week Range2.6100 - 14.9500
Volume163,558
Avg. Volume233,060
Market Cap144.787M
Beta (5Y Monthly)1.23
PE Ratio (TTM)2.13
EPS (TTM)1.2600
Earnings DateNov 24, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.05
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
25% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for JFIN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Jiayin Group Inc.
    Analyst Report: Seagen Inc.Seagen Inc. (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
    Rating
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
  • GlobeNewswire

    Jiayin Group Inc. Reports Third Quarter 2021 Unaudited Financial Results

    -- Third Quarter Total Loan Origination Volume grew 100.2% to RMB6,668 million ---- Third Quarter Net Income grew 41.2% to RMB124.8 million -- SHANGHAI, China, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Jiayin Group Inc. (“Jiayin” or the “Company”) (NASDAQ: JFIN), a leading fintech platform in China, today announced its unaudited financial results for the third quarter ended September 30, 2021. Third Quarter 2021 Operational and Financial Highlights : Loan origination volume1 was RMB6,668 million (US$1,0

  • Zacks

    Jiayin (JFIN) to Release Q3 Earnings: What's in the Cards?

    Jiayin's (JFIN) third-quarter 2021 performance is likely to have benefited from an expanding partner base and a robust increase in asset quality and loan growth.

  • GlobeNewswire

    Jiayin Group Inc. to Release Third Quarter 2021 Unaudited Results on Wednesday, November 24, 2021

    SHANGHAI, China, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Jiayin Group Inc. (“Jiayin” or the “Company”) (NASDAQ: JFIN), a leading fintech platform in China, today announced that it will release its financial results for the third quarter 2021 before the U.S market opens on Wednesday, November 24, 2021. The company will conduct a conference call on Wednesday, November 24, 2021 at 8:00 AM U.S. Eastern Time (9:00 PM Beijing/Hong Kong Time). What:Jiayin Group Third Quarter 2021 Earnings Conference CallWhen

Advertisement
Advertisement